NYSE · ABBV
AbbVie Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ABBV: Oct 30, 2026
AbbVie Inc. Common Stock is expected to report earnings on 10/30/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $3.74. The reported EPS for the same quarter last year was $1.86.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $3.74 | $3.77 | $3.69 | 5 |
| Dec 2026 | $3.91 | $4.18 | $3.79 | 6 |
| Mar 2027 | $3.37 | $3.40 | $3.34 | 3 |
| Jun 2027 | $4.06 | $4.16 | $3.93 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · BNK Invest · The Motley Fool- RTTNews · Oct 29, 6:54 AM EDTAbbVie's QULIPTA Outperforms Topiramate In Phase 3 Migraine Prevention Study(RTTNews) – AbbVie (ABBV) reported that its migraine-prevention drug QULIPTA (atogepant) demonstrated better tolerability and efficacy than Topiramate in the Phase 3 TEMPLE study, with fewer patients discontinuing treatment due to side effects and more achieving a substantial red
- RTTNews · Oct 28, 10:57 AM EDTAbbVie's BOTOX Cosmetic Day Returns November 18 With Special Offers(RTTNews) – Allergan Aesthetics, an AbbVie company (ABBV), will celebrate BOTOX Cosmetic Day on November 18, 2026, offering special promotions through its Alle loyalty program.
- Zacks · Oct 28, 9:33 AM EDTHow Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?Eli Lilly is expanding beyond GLP-1 drugs as neuroscience and immunology therapies fuel growth ahead of Q3 results, with Kisunla, Taltz and newer drugs in focus.
- Zacks · Oct 28, 3:29 AM EDTThe Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVieEli Lilly, Novartis, Johnson & Johnson and AbbVie advance arthritis treatment portfolios through strong drug sales, clinical progress and regulatory expansions.
- Zacks · Oct 27, 11:16 AM EDT4 Arthritis Drug Stocks Investors Should Monitor for Growth PotentialLLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
- BNK Invest · Oct 27, 10:57 AM EDTNotable ETF Inflow Detected – SPYV, BAC, ABBV, NEELooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR Portfolio S&P 500 Value ETF (Symbol: SPYV) where we have detected an approximate $351.9 million dollar inflow — that's a 0.9%
- Zacks · Oct 27, 10:32 AM EDTBuy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 EarningsAbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise near-term concerns.
- Zacks · Oct 27, 9:47 AM EDTWhat's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
- RTTNews · Oct 27, 9:33 AM EDTAbbVie Submits FDA Application For Etentamig In Multiple Myeloma(RTTNews) – AbbVie (ABBV) has submitted a Biologics License Application to the U.S. FDA for investigational Etentamig to treat adults with relapsed or refractory multiple myeloma, following positive Phase 3 results.
- The Motley Fool · Oct 26, 2:50 AM EDTBillionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a BuyAbbVie has increased its annual dividend for five decades.
- RTTNews · Oct 23, 9:53 PM EDTAbbVie Gains FDA Approval For Subcutaneous Induction Of SKYRIZI In Crohn's Disease(RTTNews) – AbbVie (ABBV) announced that the U.S. Food and Drug Administration approved a subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease, providing patients with a new option to begin treatment at home.
- RTTNews · Oct 23, 10:53 AM EDTWeekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) – Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for AbbVie Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.